EC Number |
Inhibitors |
Structure |
---|
3.4.17.23 | Ile-Pro-Pro |
inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2 |
|
3.4.17.23 | isocryptolepine |
binding energy to SARS-CoV-2 spike protein is -9.7 kcal/mol |
|
3.4.17.23 | isoniazid pyruvate |
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex |
|
3.4.17.23 | isothymol |
inhibition of the ACE2 enzyme |
|
3.4.17.23 | ivermectin |
inhibition of the ACE2 enzyme; potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex |
|
3.4.17.23 | ivermectin |
binding affinity -10.87 kcal/mol, favorable binding modes, critical interactions, and pharmaceutical properties |
|
3.4.17.23 | Leu-Pro-Pro |
inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2 |
|
3.4.17.23 | lumacaftor |
inhibits viral replication in a Vero-E6 cell-based SARS-CoV-2 infection assay |
|
3.4.17.23 | luteolin |
shows a strong affinity for the active site of ACE2, ACE2-inhibitor complexes display structural stability with suitable binding energies |
|
3.4.17.23 | menthol |
potential inhibitor of the SARS-CoV-2-S protein:ACE2 complex |
|